Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
24.17
+0.20 (0.86%)
At close: Oct 28, 2025, 4:00 PM EDT
24.15
-0.02 (-0.06%)
After-hours: Oct 28, 2025, 4:00 PM EDT
Castle Biosciences Revenue
Castle Biosciences had revenue of $86.19M in the quarter ending June 30, 2025, a decrease of -0.94%. This brings the company's revenue in the last twelve months to $346.27M, up 20.40% year-over-year. In the year 2024, Castle Biosciences had annual revenue of $332.07M with 51.09% growth.
Revenue (ttm)
$346.27M
Revenue Growth
+20.40%
P/S Ratio
1.96
Revenue / Employee
$455,018
Employees
761
Market Cap
700.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 332.07M | 112.28M | 51.09% |
| Dec 31, 2023 | 219.79M | 82.75M | 60.38% |
| Dec 31, 2022 | 137.04M | 42.95M | 45.65% |
| Dec 31, 2021 | 94.09M | 31.44M | 50.18% |
| Dec 31, 2020 | 62.65M | 10.78M | 20.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CSTL News
- 9 hours ago - Castle Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 days ago - New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett's Esophagus - GlobeNewsWire
- 4 days ago - New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference - GlobeNewsWire
- 15 days ago - Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025 - GlobeNewsWire
- 27 days ago - Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine - GlobeNewsWire
- 5 weeks ago - Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award - GlobeNewsWire
- 5 weeks ago - Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025 - GlobeNewsWire
- 7 weeks ago - New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions - GlobeNewsWire